11Beta-hydroxyprogesteroneCAS# 600-57-7 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 600-57-7 | SDF | Download SDF |
| PubChem ID | 101788 | Appearance | White powder |
| Formula | C21H30O3 | M.Wt | 330.46 |
| Type of Compound | Steroids | Storage | Desiccate at -20°C |
| Synonyms | 11β-Hydroxyprogesterone | ||
| Solubility | DMSO : 50 mg/mL (151.30 mM; Need ultrasonic) | ||
| Chemical Name | (8S,9S,10R,11S,13S,14S,17S)-17-acetyl-11-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one | ||
| SMILES | CC(=O)C1CCC2C1(CC(C3C2CCC4=CC(=O)CCC34C)O)C | ||
| Standard InChIKey | BFZHCUBIASXHPK-ATWVFEABSA-N | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | The progesterone derivatives 11 alpha- and 11 beta-hydroxyprogesterone are potent inhibitors of 11 beta-hydroxysteroid dehydrogenase (isoforms 1 and 2) in vitro and can confer mineralocorticoid activity on corticosterone in the rat in vivo. 11beta-Hydroxyprogesterone acts as a mineralocorticoid agonist in stimulating Na+ absorption in mammalian principal cortical collecting duct cells. |
| Targets | Sodium Channel |
| In vivo | 11alpha- and 11beta-hydroxyprogesterone, potent inhibitors of 11 beta-hydroxysteroid dehydrogenase, possess hypertensinogenic activity in the rat.[Pubmed: 8698448]Hypertension. 1996 Mar;27(3 Pt 1):421-5.The progesterone derivatives 11alpha-hydroxyprogesterone and 11Beta-hydroxyprogesterone are potent inhibitors of 11 beta-hydroxysteroid dehydrogenase (isoforms 1 and 2) in vitro and can confer mineralocorticoid activity on corticosterone in the rat in vivo. 11beta-Hydroxysteroid dehydrogenase metabolizes active glucocorticoids to their inactive 11-dehydro products and protects renal mineralocorticoid receptors from the high circulating levels of endogenous glucocorticoids. 11 beta-Hydroxysteroid dehydrogenase has been suggested to be important not only in the control of renal sodium retention but also of blood pressure.
|
| Structure Identification | Mol Pharmacol. 2002 Dec;62(6):1306-13.11Beta-hydroxyprogesterone acts as a mineralocorticoid agonist in stimulating Na+ absorption in mammalian principal cortical collecting duct cells.[Pubmed: 12435797]The binding of mineralocorticoid hormones to the mineralocorticoid receptor is the first step in a cascade of events leading to the stimulation of Na(+) reabsorption by renal cortical collecting duct (CCD) principal cells. The agonist properties of mineralocorticoid hormones are linked to contacts between their 21-hydroxyl group and Asn770, a residue of the ligand-binding domain of the human mineralocorticoid receptor (hMR). |
11Beta-hydroxyprogesterone Dilution Calculator
11Beta-hydroxyprogesterone Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.0261 mL | 15.1304 mL | 30.2608 mL | 60.5217 mL | 75.6521 mL |
| 5 mM | 0.6052 mL | 3.0261 mL | 6.0522 mL | 12.1043 mL | 15.1304 mL |
| 10 mM | 0.3026 mL | 1.513 mL | 3.0261 mL | 6.0522 mL | 7.5652 mL |
| 50 mM | 0.0605 mL | 0.3026 mL | 0.6052 mL | 1.2104 mL | 1.513 mL |
| 100 mM | 0.0303 mL | 0.1513 mL | 0.3026 mL | 0.6052 mL | 0.7565 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
11beta-Hydroxyprogesterone is a potent inhibitors of 11β-Hydroxysteroid dehydrogenase; also activates human mineralocorticoid receptor in COS-7 cells with an ED50 of 10 nM.
In Vitro:11OHP displays agonist mineralocorticoid activity. 11β-hydroxyprogesterone activates the transiently expressed hMR in COS-7 cells in a dose-dependent manner with an ED50 of 10 nM and stimulates Ams/sc in mpkCCDcl4 cells. Docking 11β-hydroxyprogesterone within the hMR-ligand-binding domain homology model reveals that the agonist activity of 11OHP is caused by contacts between its 11β-hydroxyl group and Asn770[1].
In Vivo:11β-hydroxyprogesterone causes a significant elevation in blood pressure within 3 days, an effect that persisted throughout the 14-day infusion. 11β-hydroxyprogesterone is potently hypertensinogenic in the rat and that this activity depends on an intact adrenal and at least in part on the activation of mineralocorticoid receptors[2].
References:
[1]. Rafestin-Oblin ME, et al. 11beta-hydroxyprogesterone acts as a mineralocorticoid agonist in stimulating Na+ absorption in mammalian principal cortical collecting duct cells. Mol Pharmacol. 2002 Dec;62(6):1306-13.
[2]. Souness GW, et al. 11 alpha- and 11 beta-hydroxyprogesterone, potent inhibitors of 11 beta-hydroxysteroid dehydrogenase, possess hypertensinogenic activity in the rat. Hypertension. 1996 Mar;27(3 Pt 1):421-5.
- N-Me-DL-Ala-OH.HCl
Catalog No.:BCC2618
CAS No.:600-21-5
- Adenosine cyclophosphate
Catalog No.:BCN2190
CAS No.:60-92-4
- Phloretin
Catalog No.:BCN4128
CAS No.:60-82-2
- Phlorizin
Catalog No.:BCN4126
CAS No.:60-81-1
- Antipyrine
Catalog No.:BCC8834
CAS No.:60-80-0
- Veratramine
Catalog No.:BCN2965
CAS No.:60-70-8
- Methimazole
Catalog No.:BCC3812
CAS No.:60-56-0
- Tetracycline
Catalog No.:BCC9176
CAS No.:60-54-8
- Acetyl-Strophanthidin
Catalog No.:BCC8113
CAS No.:60-38-8
- Acetamide
Catalog No.:BCN4114
CAS No.:60-35-5
- Linoleic acid
Catalog No.:BCN3821
CAS No.:60-33-3
- (6-)ε-Aminocaproic acid
Catalog No.:BCC4888
CAS No.:60-32-2
- Oblongine
Catalog No.:BCN4103
CAS No.:60008-01-7
- Glabrene
Catalog No.:BCN6692
CAS No.:60008-03-9
- Chlormethiazole hydrochloride
Catalog No.:BCC6830
CAS No.:6001-74-7
- BOC-L-6-HYDROXYNORLEUCINE
Catalog No.:BCN2360
CAS No.:77611-37-1
- Alizarin 2-methyl ether
Catalog No.:BCN3480
CAS No.:6003-11-8
- GL3
Catalog No.:BCN8180
CAS No.:60037-39-0
- N-Demethylechitamine
Catalog No.:BCN4104
CAS No.:60048-88-6
- Bay 65-1942 free base
Catalog No.:BCC1408
CAS No.:600734-02-9
- Bay 65-1942 HCl salt
Catalog No.:BCC1409
CAS No.:600734-06-3
- Secologanic acid
Catalog No.:BCN8214
CAS No.:60077-46-5
- Vogeloside
Catalog No.:BCN6737
CAS No.:60077-47-6
- (1)Benzopyrano(3,4-b)furo(2,3-h)(1)benzopyran-6(12H)-one, 1,2,-dihydro-5-hydroxy-8,9-dimethoxy-2-(1-methylethenyl)-, (R)-
Catalog No.:BCN8538
CAS No.:60077-62-5
11 alpha- and 11 beta-hydroxyprogesterone, potent inhibitors of 11 beta-hydroxysteroid dehydrogenase, possess hypertensinogenic activity in the rat.[Pubmed:8698448]
Hypertension. 1996 Mar;27(3 Pt 1):421-5.
The progesterone derivatives 11 alpha- and 11 beta-hydroxyprogesterone are potent inhibitors of 11 beta-hydroxysteroid dehydrogenase (isoforms 1 and 2) in vitro and can confer mineralocorticoid activity on corticosterone in the rat in vivo. 11 beta-Hydroxysteroid dehydrogenase metabolizes active glucocorticoids to their inactive 11-dehydro products and protects renal mineralocorticoid receptors from the high circulating levels of endogenous glucocorticoids. 11 beta-Hydroxysteroid dehydrogenase has been suggested to be important not only in the control of renal sodium retention but also of blood pressure. To assess the possible blood pressure-modulating effects of 11 alpha- and 11 beta-hydroxyprogesterone, we infused these substances into both intact and adrenalectomized Sprague-Dawley rats continuously for 14 days. Both 11 alpha- and 11 beta-hydroxyprogesterone caused a significant elevation in blood pressure within 3 days, an effect that persisted throughout the 14-day infusion. The hypertensive effects of 11 alpha-hydroxyprogesterone were abolished by adrenalectomy and significantly attenuated when 11 alpha-hydroxyprogesterone was infused together with the specific mineralocorticoid receptor antagonist RU28318. In an additional series of experiments, 11 alpha-hydroxyprogesterone significantly amplified the hypertensive effects of corticosterone in adrenalectomized spontaneously hypertensive rats but had no effects by itself in this experimental animal. These results demonstrate that both 11 alpha- and 11 beta-hydroxyprogesterone are potently hypertensinogenic in the rat and that this activity depends on an intact adrenal and at least in part on the activation of mineralocorticoid receptors. 11 beta-Hydroxyprogesterone, and similar endogenous progesterone metabolites that inhibit 11 beta-hydroxysteroid dehydrogenase, may be involved in the pathology of certain hypertensive states.
11beta-hydroxyprogesterone acts as a mineralocorticoid agonist in stimulating Na+ absorption in mammalian principal cortical collecting duct cells.[Pubmed:12435797]
Mol Pharmacol. 2002 Dec;62(6):1306-13.
The binding of mineralocorticoid hormones to the mineralocorticoid receptor is the first step in a cascade of events leading to the stimulation of Na(+) reabsorption by renal cortical collecting duct (CCD) principal cells. The agonist properties of mineralocorticoid hormones are linked to contacts between their 21-hydroxyl group and Asn770, a residue of the ligand-binding domain of the human mineralocorticoid receptor (hMR). Here, we investigate whether the presence of a hydroxyl group at position 11, 17, or 20 could also alter the activity of progesterone (P), a mineralocorticoid antagonist without the 21-hydroxyl group. Both 17 alpha-hydroxyprogesterone (17OHP) and 20 alpha-hydroxyprogesterone (20OHP) antagonized the aldosterone-induced trans-activation activity (IC(50): 17OHP, 10(-7) M; 20OHP, 10(-8) M) of the hMR transiently expressed in COS-7 cells lacking steroid receptors. In cultured mouse mpkCCD(cl4) principal cells, 17OHP and 20OHP also prevented the aldosterone-stimulated amiloride-sensitive component of the short-circuit current (Ams I(sc)), reflecting Na(+) absorption mediated by the epithelial Na(+) channel (ENaC). In contrast, 11 beta-hydroxyprogesterone (11OHP) activated the transiently expressed hMR in COS-7 cells in a dose-dependent manner (ED(50): 10(-8) M) and, like aldosterone, stimulated Ams I(sc) in mpkCCD(cl4) cells. Docking 11OHP within the hMR-ligand-binding domain homology model revealed that the agonist activity of 11OHP is caused by contacts between its 11 beta-hydroxyl group and Asn770. Furthermore, 11OHP was unable to activate the mutant hMR/N770A, in which Ala is substituted for Asn at position 770. These findings demonstrate that in the absence of the 21-hydroxyl group, the 11 beta-hydroxyl group can produce the contact with the hMR-Asn770 required for the hMR activation leading to stimulated Na(+) absorption.
